Scarica l'app Stockscreener
17.77
2.68%
-0.49
Dopo l'orario di chiusura:
17.92
0.15
+0.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
How risky is Dyne Therapeutics Inc. stock now2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
Why hedge funds are buying Dyne Therapeutics Inc. stockJuly 2025 Market Mood & Detailed Earnings Play Strategies - ulpravda.ru
$350 million fundraise shows potential of novel DMD therapy - The Pharma Letter
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus - TechStock²
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.7%What's Next? - MarketBeat
Liquidity Mapping Around (DYN) Price Events - Stock Traders Daily
Dyne Therapeutics (DYN) climbs 9.5% on stellar results for DMD therapy candidate - MSN
Dyne Therapeutics Earnings Notes - Trefis
Free cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Free cash flow per share of Dyne Therapeutics, Inc. – BOATS:DYN - TradingView — Track All Markets
CapEx per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Operating cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
First Week of February 2026 Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
DYN (Dyne Therapeutics) EV-to-OCF : -7.12 (As of Dec. 27, 2025) - GuruFocus
Why analysts see a huge upside for Dyne Therapeutics (DYN) - MSN
Dyne Therapeutics (DYN): Valuation Check After Board Addition Signals Next Phase of Commercial Growth - Sahm
Dyne Therapeutics appoints Vikram Karnani to board of directors By Investing.com - Investing.com Nigeria
Dyne Therapeutics Bets Big On Breakthrough Muscle Disease Treatments - Finimize
Dyne Therapeutics (DYN): Reaffirmed Buy Ratings Prompt Fresh Look at Valuation After Neuromuscular Data Update - Yahoo Finance
Dyne Therapeutics appoints Vikram Karnani to board of directors - Investing.com
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Deep Dive Into Its 87% Potential Upside - DirectorsTalk Interviews
Dyne Therapeutics Appoints Vikram Karnani to Board - TipRanks
Dyne Therapeutics appoints Vikram Karnani to board - MSN
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - The Manila Times
Dyne Therapeutics Appoints Vikram Karnani as Independent Director - TradingView — Track All Markets
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors to Support Commercialization Efforts - Quiver Quantitative
Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors - TradingView — Track All Markets
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) - Finviz
Dyne Therapeutics (DYN) Price Target Increased by 12.57% to 39.97 - Nasdaq
Dyne Therapeutics, Inc. $DYN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Understanding the Setup: (DYN) and Scalable Risk - news.stocktradersdaily.com
Will Dyne Therapeutics Inc. stock gain from government policiesTrade Analysis Report & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Will Dyne Therapeutics Inc. stock reach all time highs in 2025Quarterly Trade Summary & Low Risk Profit Maximizing Plans - DonanımHaber
DYN (Dyne Therapeutics) EV-to-OCF : -6.50 (As of Dec. 19, 2025) - GuruFocus
Can Dyne Therapeutics Inc. stock deliver consistent earnings growth2025 Volatility Report & Safe Swing Trade Setup Alerts - DonanımHaber
Dyne to seek accelerated approval of DMD drug on Phase I/II data - MSN
Why Dyne Therapeutics stock tanked on Tuesday - MSN
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus - The Globe and Mail
Oppenheimer upgrades Dyne Therapeutics to outperform, raises target to $40 - MSN
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha
Evercore ISI Maintains and Lowers Price Target for Dyne Therapeu - GuruFocus
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Frazier Life Sciences Management L.P. Has $14.34 Million Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
TFG Asset Management GP Ltd Acquires New Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
Braidwell LP Has $31.16 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):